Board of Directors
J. Patrick Mackin
Chairman, President, and Chief Executive Officer
J. Patrick Mackin has served as President and Chief Executive Officer of CryoLife since September 2014. He was appointed to the CryoLife Board in October 2014, and Chairman of the Board in April 2015. Mr. Mackin has more than 20 years of experience in the medical device industry. Prior to joining CryoLife, Mr. Mackin served as President of Cardiac Rhythm Disease Management, the largest operating division of Medtronic, Inc., from August 2007 to August 2014. At Medtronic, he previously held the positions of Vice President, Vascular, Western Europe and Vice President and General Manager, Endovascular Business Unit. Prior to joining Medtronic in 2002, Mr. Mackin worked for six years at Genzyme, Inc. serving as Senior Vice President and General Manager for the Cardiovascular Surgery Business Unit and as Director of Sales, Surgical Products division. Before joining Genzyme, Mr. Mackin spent five years at Deknatel/Snowden-Pencer, Inc. in various sales and marketing roles and three years as an Officer in the U.S. Army. Mr. Mackin received an MBA from the Kellogg Graduate School of Management at Northwestern University and is a graduate of the U.S. Military Academy at West Point.
Thomas F. Ackerman
Executive Vice President and Chief Financial Officer, Charles River Laboratories
Thomas F. Ackerman has served as a Director of CryoLife since December 2003. Mr. Ackerman currently serves as a financial consultant to Charles River Laboratories International, Inc. Mr. Ackerman served as Executive Vice President and Chief Financial Officer of Charles River Laboratories International, Inc. until August 2015, (NYSE: CRL), a position he held since 2005. Charles River Laboratories is a full service, early-stage contract research organization. Mr. Ackerman joined Charles River Laboratories in 1988 with over eleven years of combined public accounting and international finance experience. He was named Controller, North America in 1992 and became Vice President and Chief Financial Officer in 1996. In 1999, he was named a Senior Vice President, and in 2005 he was named a Corporate Executive Vice President. Prior to joining Charles River Laboratories, Mr. Ackerman was an accountant at Arthur Andersen & Co. Mr. Ackerman is a Director of the University of Massachusetts Amherst Foundation. Mr. Ackerman received a B.S. in Accounting from the University of Massachusetts and became a certified public accountant in 1979 (his license is currently inactive).
Daniel J. Bevevino
Retired Vice President and Chief Financial Officer, Respironics, Inc.
Daniel J. Bevevino has served as a Director of CryoLife since December 2003. From 1996 until March of 2008, Mr. Bevevino served as the Vice President and Chief Financial Officer of Respironics, Inc. (Nasdaq: RESP), a company that develops, manufactures, and markets medical devices used primarily for the treatment of patients suffering from sleep and respiratory disorders, where he was employed since 1988. In March 2008, Respironics was acquired by Royal Philips Electronics (NYSE: PHG), whose businesses include a variety of medical solutions including medical diagnostic imaging and patient monitoring systems, as well as businesses focused on energy efficient lighting and consumer products. From March 2008 to December 31, 2009, Mr. Bevevino was employed by Philips as the Head of Post-Merger Integration – Respironics, as well as in various operating capacities, to help facilitate the integration of the combined companies. He is currently an independent consultant providing interim chief financial officer services and other business advisory services in the life sciences industry, and he currently serves as a director of one of the companies for which he provides services. He began his career as a certified public accountant with Ernst & Young (his license is currently inactive). Mr. Bevevino received a B.S. in Business Administration from Duquesne University and an MBA from the University of Notre Dame.
President and Chief Executive Officer, Zyga Technology
Jim Bullock has served as a Director of CryoLife since October 2016. Jim joined Zyga Technology as President and Chief Executive Officer (CEO) in Nov. 2011. Prior, he served as President and CEO of Atritech, Inc. until it was sold to Boston Scientific and of Endocardial Solutions, Inc., which was acquired by St. Jude Medical. Jim began his career at American Hospital Supply, which was later acquired by Baxter Healthcare. During his 13 years at the company, Jim served in a variety of Sales & Marketing leadership positions. He holds a Bachelor of Science degree in Hospital Administration from the University of Arizona.
Chief Executive Officer, NxStage Medical Inc.
Jeff Burbank is the Chief Executive Officer of NxStage Medical Inc., and a member of the Board of Directors. He has served in these positions since he founded the company in December 1998. Jeff has over 30 years of in-depth management experience with companies developing, marketing, and manufacturing products for ESRD patients. He has led NxStage since its inception, guiding it through all of its developmental phases to the successful initiation and rapid growth of commercial activities, its initial public offering, the acquisition of Medisystems Corporation, the evolution of the product line, and into services. Prior to founding NxStage, Jeff co-founded Vasca, Inc., a company providing innovative implantable access devices, where he was the President and Chief Executive Officer, as well as Chairman of the Board. He gained significant renal industry experience during his nine years in the Renal Division at Gambro, Inc., a medical technology company, with his last position as Director of Marketing and Advanced Technologies. During his career, he has been an inventor on over 50 U.S. patents for medical devices. Jeff received his BS in Industrial Engineering from Lehigh University.
Ronald D. McCall, Esq.
Presiding Director, Attorney at Law
Ronald D. McCall, Esq. has served as a Director of CryoLife since January 1984. From 1985 to the present, Mr. McCall has been the owner of the law firm of Ronald D. McCall,
P. A., based m Tampa, Florida. Mr. McCall was admitted to the practice of law in Florida in 1961. Mr. McCall received his B.A. degree from the University of Florida in 1958 and LLB with honors 1961. Member of Phi Kappa Phi 1959. Florida Blue Key 1957; Hall of Fame 1957; Executive Editor University of Florida Law Review 1960. Chairman, Florida Council of Bar Association Presidents 1976-1977. Director of Hillsborough County Bar Association and President (1973-1974): Former member of Board of Directors, Winter Haven Citrus Growers Association; Board of Trustees and President Gulf Coast Lung Association 1978-1979.
Retired Managing Director, Bentley Associates L.P.
New York, New York
Harvey Morgan has served as a Director of CryoLife since May 2008. Mr. Morgan has more than 40 years of investment banking experience, with significant expertise in strategic advisory services, mergers and acquisitions, private placements, and underwritings. He served as a Managing Director of the investment banking firm Bentley Associates, L.P. from 2004 to December 31, 2012, and from 2001 to 2004 he was a Principal of Shattuck Hammond Partners, an independent investment banking and financial advisory firm. Mr. Morgan also serves on the Board of Family Dollar Stores, Inc. (NYSE: FDO) and previously served on the Board of Cybex International, Inc. (Nasdaq: CYBI). Mr. Morgan received his undergraduate degree from The University of North Carolina at Chapel Hill and an MBA from The Harvard Business School.
Jon W. Salveson
Vice Chairman, Investment Banking, Piper Jaffray Companies
Jon W. Salveson has served as a Director of CryoLife since May 2012. Mr. Salveson is the Vice Chairman, Investment Banking and Chairman of the Healthcare Investment Banking Group at Piper Jaffray Companies (NYSE: PJC). He joined Piper Jaffray in 1993 as an associate, was elected Managing Director in 1999, and was named the Group Head of Piper Jaffray’s international healthcare investment banking group in 2001. Mr. Salveson was appointed Global Head of Investment Banking and a member of the Executive Committee of Piper Jaffray in 2004, and has served in his present position as Vice Chairman, Investment Banking since July 2010. Mr. Salveson also serves on the Board of Sunshine Heart, Inc. (NASDAQ: SSH). Mr. Salveson received his undergraduate degree from St. Olaf College and an M.M.M. in finance from the Kellogg Graduate School of Management at Northwestern University.
Marna P. Borgstrom
Chief Executive Officer, Yale New Haven Health and Yale New Haven Hospital
Marna Borgstrom joined the CryoLife Board in June of 2018. She currently serves as the Chief Executive Officer of Yale New Haven Hospital and Yale New Haven Health, positions she has held since 2005. With revenues of $4.5B, Yale New Haven Health is the largest health system in the region, the primary teaching partner of Yale University’s School of Medicine, and the largest private employer in Connecticut.
Marna chairs the boards of the Healthcare Institute and the Coalition to Protect America’s Healthcare and is the immediate past chair of Vizient, a Dallas, Texas-based health care company. She serves on several other boards including The Connecticut Hospital Association and New Haven Promise, an educational initiative designed to increase high school graduation rates and support college tuition for economically disadvantaged students.
Marna received her undergraduate degree from Stanford University and was awarded a master’s of public health by the Yale University School of Epidemiology and Public Health. She is a lecturer at the Yale School of Epidemiology and Public Health, from which she received the Distinguished Alumni Award in 2018.